Protagonist Therapeutics, Inc — Director's Dealing 2016

Aug 11, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2016-08-10

Reporting Person: Papanek Julie (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (1869922)		Indirect

Footnotes

F1: The number of shares of common stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Each share of the Issuer's Series C Preferred Stock is convertible into the Issuer's common stock on a 1-for-14.5 basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects the 1-for-14.5 reverse stock split pursuant to which every 14.5 shares of Series C Preferred Stock will convert into one share of common stock of the Issuer, effective upon the closing of the Issuer's initial public offering, for no additional consideration.

F2: These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The Reporting Person is a non-managing member of Canaan Partners X LLC, the general partner of the Canaan Fund. The Reporting Person does not have voting, investment or dispositive power over any of the shares directly held by the Canaan Fund and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.